Masitinib mesylate for metastatic and non‐resectable canine cutaneous mast cell tumours |
| |
| Authors: | O A Smrkovski L Essick B W Rohrbach A M Legendre |
| |
| Institution: | Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA |
| |
| Abstract: | Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non‐metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non‐metastatic canine MCTs. Identification of toxicities and prognostic factors in these dogs was of secondary interest. Twenty‐six dogs were included in this study. The overall response rate to masitinib was 50%. The median survival time for dogs that responded to masitinib was 630 days versus 137 days for dogs that did not respond (P = 0.0033). Toxicity was recorded in 61.5% of treated dogs, but the majority of adverse events were mild and self‐limiting. Response to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs. |
| |
| Keywords: | dog mast cell tyrosine kinase inhibitor |
|
|
